angiotensin ii has been researched along with B16 Melanoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akitake, Y; Hosoda, H; Imamichi, Y; Ishikane, S; Kangawa, K; Kawabe, S; Kimura, T; Miura, K; Miyamoto, K; Miyazato, M; Mizutani, T; Nojiri, T; Takahashi-Yanaga, F; Tokudome, T; Toyohira, Y; Yanagihara, N | 1 |
| Bagrov, DV; Chemeris, NK; Durymanov, MO; Kedrov, AV; Klinov, DV; Rosenkranz, AA; Sobolev, AS; Yarutkin, AV | 1 |
| Anderson, ZJ; Elias, PD; Harding, JW; Hudson, BD; Masino, JA; McCoy, AT; Sardinia, MF; Varnum, MD; Wright, JW; Yamamoto, BJ | 1 |
| Harding, JW; Kawas, LH; McCoy, AT; Wright, JW; Yamamoto, BJ | 1 |
4 other study(ies) available for angiotensin ii and B16 Melanoma
| Article | Year |
|---|---|
Angiotensin II promotes pulmonary metastasis of melanoma through the activation of adhesion molecules in vascular endothelial cells.
Topics: Angiotensin II; Animals; Cell Adhesion Molecules; Cell Proliferation; Dose-Response Relationship, Drug; Endothelial Cells; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Knockout; Random Allocation | 2018 |
Application of vasoactive and matrix-modifying drugs can improve polyplex delivery to tumors upon intravenous administration.
Topics: Administration, Intravenous; Angiotensin II; Animals; Cell Line, Tumor; Collagen Type I; DNA; Drug Delivery Systems; Female; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Green Fluorescent Proteins; Losartan; Luciferases, Firefly; Melanoma, Experimental; Mice, Inbred C57BL; Mice, Inbred DBA; Nanoparticles; Nitroglycerin; Oligopeptides; Polyethylene Glycols; Polyethyleneimine; Receptor, Melanocortin, Type 1; Regional Blood Flow; Vasoconstrictor Agents; Vasodilator Agents | 2016 |
The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor.
Topics: Angiogenesis Inhibitors; Angiotensin II; Animals; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dogs; Endothelial Cells; Endothelium, Vascular; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Hepatocyte Growth Factor; Humans; In Vitro Techniques; Lung; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Oligopeptides; Proto-Oncogene Proteins c-met; Radioligand Assay; Signal Transduction | 2010 |
Development of angiotensin IV analogs as hepatocyte growth factor/Met modifiers.
Topics: Angiotensin II; Animals; Cell Proliferation; Cells, Cultured; Dogs; Hepatocyte Growth Factor; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Oligopeptides; Protein Multimerization; Proto-Oncogene Proteins c-met; Rats; Rats, Sprague-Dawley; Signal Transduction | 2012 |